title: Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
authors.affiliation: Unita Reumatologica, Hospital of Prato, Prato, Italy. fcantini@usl4.toscana.it
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Cantini
authors.forename: Laura
authors.initials: L
authors.lastname: Niccoli
authors.forename: Maurizio
authors.initials: M
authors.lastname: Benucci
authors.forename: Daniela
authors.initials: D
authors.lastname: Chindamo
authors.forename: Carlotta
authors.initials: C
authors.lastname: Nannini
authors.forename: Ignazio
authors.initials: I
authors.lastname: Olivieri
authors.forename: Angela
authors.initials: A
authors.lastname: Padula
authors.forename: Carlo
authors.initials: C
authors.lastname: Salvarani
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004361:Drug Tolerance; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept